Response of astrocytoma to high‐dose methotrexate with citrovorum factor rescue
Response of astrocytoma to high‐dose methotrexate with citrovorum factor rescue
复制标题
星形细胞瘤对大剂量甲氨蝶呤联合柠檬酸因子拯救的反应
作者：
I. Djerassi;Jung Sun Kim;A. Reggev
11例星形细胞瘤患者接受了高剂量甲氨蝶呤（HDMTX）和柠檬酸因子补救（CFR）治疗。在8例患者中观察到临床应答，包括4/4例3级疾病，1/1例2 - 3级，2/4例4级，1/1例未指明的低级别肿瘤。两名4级患者和一名1级疾病患者未能应答。8例反应中有6例通过影像学记录。这些患者中有3例存活且健康，未接受15+、4.5+和1.5+年的进一步治疗。第四名存活患者存活2年以上，并在继续治疗下有所改善。4例存活患者复发2 - 3级或3级疾病。HDMTX-CFR对星形细胞瘤有效。它的最大价值可能是在复发的3级疾病。
Eleven patients with astrocytoma were treated with high‐dose methotrexate (HDMTX) and citrovorum factor rescue (CFR). Clinical response was observed in eight patients, including four of four with grade 3 disease, one of one with grade 2 to 3, two of four with grade four, and one of one with unspecified low‐grade tumor. Two patients with grade 4 and one with grade 1 disease failed to respond. Six of the eight responses were documented radiographically. Three of these patients are alive and well without further treatment for periods of 15+, 4.5+, and 1.5+ years. The fourth living patient is surviving 2+ years and improving under continued treatment. The four surviving patients had recurrent grade 2 to 3 or grade 3 disease. HDMTX‐CFR is effective in astrocytoma. Its greatest value may be in recurring grade 3 disease.